KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Investing Activities: 2013-2025

Historic Cash from Investing Activities for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $38.5 million.

  • Xenon Pharmaceuticals' Cash from Investing Activities rose 7637.15% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $253.8 million, marking a year-over-year increase of 246.46%. This contributed to the annual value of $165.0 million for FY2024, which is 248.13% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Cash from Investing Activities stood at $38.5 million, which was down 53.16% from $82.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $109.2 million during Q2 2024, with a 5-year trough of -$239.8 million in Q4 2023.
  • Its 3-year average for Cash from Investing Activities is $19.0 million, with a median of $38.5 million in 2025.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 1,943.03% in 2023, then spiked by 7,637.15% in 2025.
  • Xenon Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$215.4 million in 2021, then soared by 94.55% to -$11.7 million in 2022, then tumbled by 1,943.03% to -$239.8 million in 2023, then surged by 141.08% to $98.5 million in 2024, then soared by 7,637.15% to $38.5 million in 2025.
  • Its Cash from Investing Activities was $38.5 million in Q3 2025, compared to $82.3 million in Q2 2025 and $34.5 million in Q1 2025.